文献速递慢阻肺

开发并验证CE-MACE模型预测COPD急性加重后1年主要不良心血管事件

Developing and validating the CE-MACE model to predict 1-year major adverse cardiovascular events post-COPD exacerbation using routine healthcare data.
PubMed 文献 · Eur Respir J · 2026-07-23

基于英国CPRD Aurum电子健康记录,纳入338 981例≥40岁中重度COPD急性加重患者,开发并验证CE-MACE模型预测1年主要不良心血管事件(MACE)。模型保留年龄、急性加重严重程度、MACE史、mMRC呼吸困难评分、高血压和糖尿病六个预测因子,内部-外部交叉验证Harrell's C统计量为0.752,校准良好,在2%至18%风险阈值范围内净获益优于默认策略。

要点

  • COPD急性加重后1年MACE累积发生率为5.04%(95%CI 4.96-5.12%)。
  • CE-MACE模型仅含6个常规变量,区分度Harrell's C为0.752(0.746-0.759)。
  • 模型在2%至18%风险阈值范围内净获益优于默认策略,可用于风险分层。

核心结论

  • CE-MACE模型可精确识别COPD急性加重后1年MACE高风险患者,促进多学科整合医疗。

研究设计与样本

  • 使用英国CPRD Aurum电子健康记录,纳入≥40岁中重度COPD急性加重患者338 981例,采用病因特异性风险模型开发并内部-外部交叉验证。

主要发现

  • 1年MACE累积发生率为5.04%(95%CI 4.96-5.12%)。
  • 保留6个预测因子:年龄、急性加重严重程度、MACE史、mMRC呼吸困难评分、高血压和糖尿病。
  • 内部-外部交叉验证汇总Nagelkerke's R2为3.120%(2.945-3.295%),Harrell's C统计量为0.752(0.746-0.759)。
  • 校准-in-the-large为-0.006(-0.008至-0.004),校准斜率0.999(0.977-1.020)。
  • 在2%至18%风险阈值范围内净获益优于默认策略,风险分层各组累积发生率显著不同。

关键数值与推荐

  • 1年MACE累积发生率5.04%(95%CI 4.96-5.12%)。
  • Harrell's C统计量0.752(0.746-0.759),Nagelkerke's R2 3.120%(2.945-3.295%)。
  • 校准-in-the-large -0.006(-0.008至-0.004),校准斜率0.999(0.977-1.020)。
  • 净获益优于默认策略的风险阈值范围2%至18%。

临床怎么用

  • 利用常规医疗数据中的6个变量计算CE-MACE风险评分,对COPD急性加重后患者进行1年MACE风险分层。
  • 对高风险患者加强心血管危险因素管理和多学科随访。

局限性

  • 敏感性分析显示模型可推广至有任意COPD急性加重史的患者,但外部适用性仍需其他数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with COPD are at an elevated risk of cardiovascular events, particularly following acute exacerbations. Existing prediction models underestimate their risk. We developed and validated the CE-MACE model to predict 1-year major adverse cardiovascular event (MACE) risk following a COPD exacerbation. METHODS: Using electronic health records from the UK Clinical Practice Research Datalink Aurum database, we included patients ≥40 years old with moderate or severe COPD exacerbations. The outcome was fatal or non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure or ischaemic stroke). Cause-specific hazard models were used to estimate the coefficient of predictors. Model performance was assessed by Nagelkerke's R2, Harrell's C statistic, calibration-in-the-large, calibration slope and decision curve analysis. Internal-external cross validation was used to evaluate model performance across nine geographic regions. A risk score was derived from the original coefficients. RESULTS: A total of 338 981 patients were included. The overall 1-year cumulative incidence rate of MACE following COPD exacerbation was 5.04% (95% confidence interval 4.96-5.12%). Six predictors were retained: age, exacerbation severity, MACE history, modified Medical Research Council dyspnoea scale, hypertension and diabetes. In internal-external cross validation, the pooled estimation for Nagelkerke's R2 was 3.120% (2.945-3.295%) and Harrell's C statistic was 0.752 (0.746-0.759). Calibration-in-the-large was -0.006 (-0.008- -0.004) and the calibration slope was equal to 0.999 (0.977-1.020). These results suggest that the model has clinical utility, with higher net benefit than default strategies across the risk thresholds range from 2% to 18%. Model-driven risk stratification demonstrated significantly different cumulative incidence rates among these risk categories. Sensitivity analysis revealed that the CE-MACE model is generalisable to those patients with any history of COPD exacerbation. CONCLUSION: The CE-MACE model highlights the burden of cardiovascular multimorbidity in patients with COPD. The model could help precisely identify those at high risk in clinical practice and promote integrated multidisciplinary healthcare for these patients.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Wang, Ioannides, Kallis, et al. Developing and validating the CE-MACE model to predict 1-year major adverse cardiovascular events post-COPD exacerbation using routine healthcare data. Eur Respir J. 2026. PMID: 41786499. doi:10.1183/13993003.02555-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。